Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 5, 2010, Pages 536-538

  Godau, Jana ^a   Herfurth, Manon ^a   Kattner, Barbara ^a   Gasser, Thomas ^a   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; BIOLOGICAL MARKER; HUMAN GROWTH HORMONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PILOT STUDY;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS;

EID: 77952564443     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.175752     Document Type: Article

References (22)

1. Guan J, Krishnamurthi R, Waldvogel HJ, et al. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 2000;859:286-92.
2. Quesada A, Lee BY, Micevych PE. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 2008;68:632-44.
3. Krishnamurthi R, Stott S, Maingay M, et al. N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 2004;15:1601-4.
4. Offen D, Shtaif B, Hadad D, et al. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett 2001;316:129-32.
5. Domene H, Krishnamurthi K, Eshet R, et al. Growth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-I-binding protein-3, but not GH receptor gene expression in livers of juvenile rats. Endocrinology 1993;133:675-82.
6. Schaefer S, Vogt T, Nowak T, et al. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. J Neuroendocrinol 2008;20:104-9.
7. Hanew K, Sato S, Sasaki A, et al. The dopaminergic regulation of plasma growth hormone secretion in normal subjects. Tohoku J Exp Med 1986;148:151-8. (Pubitemid 16145831)
8. Vogel HP, Ketsche R. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy. J Neurol 1986;233:149-52. (Pubitemid 16114593)
9. Martignoni E, Horowski R, Liuzzi A, et al. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol 1996;19:72-80. (Pubitemid 26026323)
10. Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology (Berl) 2006;187:498-510.
11. Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992;51:541-8.
12. Lal S, Nair NP, Thavundayil JX, et al. Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication. J Neural Transm Gen Sect 1991;85:157-64.
13. Friess E, Kuempfel T, Winkelmann J, et al. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy. Arch Neurol 2001;58:241-6.
14. Llau ME, Durrieu G, Tran MA, et al. A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients. Clin Neuropharmacol 1996;19:420-7.
15. Landi F, Capoluongo E, Russo A, et al. Free insulin-like growth factor-I and cognitive function in older persons living in community. Growth Horm IGF Res 2007;17:58-66.
16. Ruprecht-Dorfler P, Klotz P, Becker G, et al. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord 2006;13:362-4.
17. Berg D, Siefker C, Ruprecht-Dorfler P, et al. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17. (Pubitemid 32059645)
18. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
19. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-31.
20. Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm Suppl 2006;71:123-32. (Pubitemid 351412114)
21. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000;55:1410-12.
22. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-300.